VJHemOnc Podcast Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
Mar 24, 2025
Join Krish Patel, an expert in mantle cell lymphoma from the Sarah Cannon Cancer Institute, and David Lewis from Plymouth University, as they discuss the groundbreaking role of BTK inhibitors in treating relapsed/refractory MCL. They explore innovative combination strategies to tackle resistance and enhance treatment efficacy. The conversation highlights the importance of personalized therapy and the evolving landscape of BTK inhibitor selection, particularly in the UK. Their insights reveal promising future directions in MCL management.
AI Snips
Chapters
Transcript
Episode notes
BTK Inhibitors as Core MCL Therapy
- BTK inhibitors are central to treating relapsed/refractory mantle cell lymphoma (MCL).
- Combining BTK inhibitors with bispecific antibodies or BCL2 antagonists shows promise for chemo-free regimens.
BTK Inhibitors as Bridge Therapy
- Use BTK inhibitors as a short-term bridge to CAR T-cell therapy in high-risk MCL patients.
- Explore BTK inhibitor backbones combined with bispecific antibodies for enhancing treatment efficacy.
Overcoming BTK Resistance
- Resistance to BTK inhibitors is an important challenge in MCL treatment.
- Non-covalent BTK inhibitors and immunotherapy combinations are promising to overcome resistance.